<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01877954</url>
  </required_header>
  <id_info>
    <org_study_id>R02511</org_study_id>
    <nct_id>NCT01877954</nct_id>
  </id_info>
  <brief_title>Qvar vs FP in Pediatrics</brief_title>
  <official_title>Comparative Effectiveness of Extrafine Hydrofluoroalkane Beclometasone Versus Fluticasone in Paediatric Patients — a Retrospective, Real-life Observational Study in a uk Primary Care Asthma Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Research in Real-Life Ltd</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Teva Pharmaceutical Industries</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Research in Real-Life Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study was to compare the absolute and relative effectiveness of
      asthma management in paediatric patients in the UK on inhaled corticosteroid (ICS)
      maintenance therapy as extra-fine HFA-BDP (Qvar®) pressurised metered dose inhaler (pMDI)
      compared with fluticasone propionate (FP) pMDI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparison of asthma control with extrafine-particle hydrofluoroalkane-beclometasone (EF
      HFA-BDP) vs fluticasone propionate (FP) in paediatric patients (5-11year olds). Patients
      identified from the General Practice Research Database (GPRD) and the Optimum Patient Care
      Research Database (OPCRD). Two analyses were conducted:

        1. Comparison of outcomes achieved by EF HFA-BDP and FP in 5-6year old patients with those
           achieved in 7-11yr old patients.

        2. Comparison of outcomes achieved by EF HFA-BDP used with or without a spacer to those
           achieved by standard particle fluticasone propionate (FP) used with a spacer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proxy risk domain asthma control</measure>
    <time_frame>One year outcome period</time_frame>
    <description>Defined as the absence of the following during the one-year outcome period:
Asthma-related:
Hospital attendance or admission, OR
A&amp;E attendance, OR
Out of hours attendance, OR
Out-patient department attendance
GP consultations for lower respiratory tract infection
Prescriptions for acute courses of oral steroids .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Asthma exacerbation rate ratio</measure>
    <time_frame>One year outcome period</time_frame>
    <description>Where exacerbations are defined as an occurrence of:
Defined as an occurrence of:
Asthma related:
Hospital admission, OR
A&amp;E attendance, OR
Use of acute oral steroids.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall asthma control</measure>
    <time_frame>One year outcome period</time_frame>
    <description>Risk domain asthma control as defined above, plus
(a)Average prescribed daily dose of albuterol or terbutaline of ≤200mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalisation rates</measure>
    <time_frame>One year outcome period</time_frame>
    <description>Asthma-related hospitalisations
Definite: Hospitalisations coded with an asthma read code
Definite and probable: Hospitalisations with an asthma read code and uncoded hospitalisations occurring within a 7-day window (either side of the hospitalisation date) of an asthma read code
Respiratory hospitalisations
Definite: Hospitalisations coded with a lower respiratory code
Definite and probable: Hospitalisations with a lower respiratory read code and uncoded hospitalisations occurring within a 7-day window (either side of the hospitalisation date) of a lower respiratory read code</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment success</measure>
    <time_frame>One year outcome period</time_frame>
    <description>Asthma control and no change in therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to ICS therapy</measure>
    <time_frame>One year outcome period</time_frame>
    <description>Categorised as: &lt;50%, 50-&lt;70%, 70-&lt;100%, ≥100%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of short-acting beta2-agonist (&quot;reliever&quot;) therapy</measure>
    <time_frame>One year outcome period</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">2654</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>IPDI Qvar</arm_group_label>
    <description>ICS initiation as Extra-fine hydrofluoroalkane beclometasone dipropionate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IPDI FP</arm_group_label>
    <description>ICS initiation as fluticasone propionate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Extra-fine hydrofluoroalkane beclometasone dipropionate</intervention_name>
    <arm_group_label>IPDI Qvar</arm_group_label>
    <other_name>Qvar®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone propionate</intervention_name>
    <arm_group_label>IPDI FP</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Asthma patients who initiate ICS therapy as one of:

        HFA-BDP pMDI FP pMDI
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged: 5-11 years

          2. Evidence of asthma (diagnostic code and/or current asthma therapy);

          3. Have at least one year of up-to-standard (UTS) baseline data (during which the step-up
             to FP/SAL occurred) and at least one year of UTS outcome data (following the IPD).

        Exclusion Criteria:

          1. Had any chronic respiratory disease, except asthma, at any time; and/or

          2. Patients on maintenance oral steroids during baseline year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Price</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research in real life</affiliation>
  </overall_official>
  <reference>
    <citation>Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Influence of particle size and patient dosing technique on lung deposition of HFA-beclomethasone from a metered dose inhaler. J Aerosol Med. 2005 Winter;18(4):379-85.</citation>
    <PMID>16379614</PMID>
  </reference>
  <reference>
    <citation>Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J. 1998 Dec;12(6):1346-53.</citation>
    <PMID>9877489</PMID>
  </reference>
  <reference>
    <citation>Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J. 2002 Feb;19(2):246-51.</citation>
    <PMID>11866004</PMID>
  </reference>
  <reference>
    <citation>Newman SP, Weisz AW, Talaee N, Clarke SW. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax. 1991 Oct;46(10):712-6.</citation>
    <PMID>1750017</PMID>
  </reference>
  <reference>
    <citation>Newman SP, Millar AB, Lennard-Jones TR, Morén F, Clarke SW. Improvement of pressurised aerosol deposition with Nebuhaler spacer device. Thorax. 1984 Dec;39(12):935-41.</citation>
    <PMID>6440305</PMID>
  </reference>
  <reference>
    <citation>Chrystyn H, Price D. Not all asthma inhalers are the same: factors to consider when prescribing an inhaler. Prim Care Respir J. 2009 Dec;18(4):243-9. doi: 10.4104/pcrj.2009.00029. Review.</citation>
    <PMID>19513494</PMID>
  </reference>
  <reference>
    <citation>Price D, Thomas M. Breaking new ground: challenging existing asthma guidelines. BMC Pulm Med. 2006 Nov 30;6 Suppl 1:S6. Review.</citation>
    <PMID>17140424</PMID>
  </reference>
  <results_reference>
    <citation>Price D, Martin RJ, Barnes N, Dorinsky P, Israel E, Roche N, Chisholm A, Hillyer EV, Kemp L, Lee AJ, von Ziegenweidt J, Colice G. Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: a real-world observational study. J Allergy Clin Immunol. 2010 Sep;126(3):511-8.e1-10. doi: 10.1016/j.jaci.2010.06.040. Epub 2010 Aug 9.</citation>
    <PMID>20692026</PMID>
  </results_reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2013</study_first_submitted>
  <study_first_submitted_qc>June 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2013</study_first_posted>
  <last_update_submitted>June 13, 2013</last_update_submitted>
  <last_update_submitted_qc>June 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hydrofluoroalkane beclomethasone</keyword>
  <keyword>fluticasone</keyword>
  <keyword>paediatrics</keyword>
  <keyword>real-life</keyword>
  <keyword>observational</keyword>
  <keyword>primary care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Beclomethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

